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INFECTIOUS  DISEASES
etter to the Editoresistance  of  gram  negative  bacteria  in hospital
cquired pneumonia:  a prospective  study
ear Editor,
ospital-acquired bacterial pneumonia (HABP) is one of the
ost important acute complications that affects patients
dmitted to intensive care units (ICU) developing mainly
n patients receiving mechanical ventilation for more  than
8 hours with an incidence of 9–27%.1,2 It is commonly caused
y species of the Enterobacteriaceae family, non-fermentative
ram-negative bacilli, and Staphylococcus aureus.3,4 The aware-
ess of the HABP and antimicrobial resistance patterns are
ecessary to improve hospital infection control system, select-
ng appropriate empirical antibiotics, reducing duration of ICU
dmission, decreasing costs of hospitalization, application of
ffective methods for preventing and controlling of HABP and
nally to reduce the mortality and morbidity rates in these
atients.
A cross-sectional study designed from January 2013 till Jan-
ary 2014 included all 16 patients admitted to the ICU with
ABP requiring mechanical ventilation for at least 48 hours
n a general hospital in south of Iran were included. Samples
ere cultured on blood agar & EMB  agar. Colony counts of more
han 104 cfu/mL were considered positive.
Table 1 – Frequency of antibiotic resistance among gram negative bacterial isolates in the study.
Antibiotic Organism
Pseudomonas aeroginoza (1) Acinetobacter baumanni (2) E. coli (2) Klebsiella pneumonia (8)
Sa Ib Rc S I R S I R S I R
Amoxicillin + clavulanate 0 0 1 0 0 2 1 0 1 2 0 6
Trimethoprim + sulfamethoxazole 0 0 1 0 0 2 0 0 2 3 0 5
Cefotaxime 0 1 0 0 0 2 0 0 2 2 2 4
Ceftazidime 1 0 0 0 0 2 1 0 1 4 0 4
Ceftriaxone 1 0 0 0 1 1 0 0 2 3 1 4
Ciproﬂoxacin 1 0 0 0 0 2 1 0 1 5 0 3
Cefazolin 0 0 1 0 0 2 0 0 2 0 0 8
Ampicillin 0 0 1 1 0 1 1 0 1 0 0 8
Amikacin 1 0 0 0 0 2 1 0 1 7 0 1
Diagnostic tests applied API-20E commercial kit for
Gram-negative bacilli & API-20NE for Gram-negative non-
fermentative bacilli. Staphylococci were identiﬁed by Gram
stain, morphology, catalase, bacitracin sensitivity, coagulase
test with fresh plasma from Darvash® Company, DNase activ-
ity, and mannitol fermentation. Susceptibility of all isolates
to different antibiotics were performed with Kirby-Bauer disk
diffusion method on Muller-Hinton agar plates. Results were
interpreted according to the standards provided by National
Committee for Clinical Laboratory Standards (NCCLS, 2003)
(Table 1).
The frequency of extended spectrum beta-lactamase
(ESBL) producing isolates were considered with double disk
synergy test (DDST) for detection of methicillin-resistant
Staphylococcus aureus (MRSA). Overall, the mortality rate of ICU
patients during the study period was 62% whereas the case
fatality rate (CFR) of HABP was 25% (4/16) with an attributable
mortality rate was 6.45%.
The risk factors for HABP mortality were: (1) male gender;
(2) increasing age; (3) underlying diseases (diabetes and car-
diovascular diseases); (4) MRSA colonization of the respiratory
tract; (5) invasive procedures; (6) resistance to cephalosporins,Imipenem 1 0 0 0 
a Susceptible.
b Intermediate.
c Resistant.0 2 2 0 0 6 0 2
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carbapenems, and aminoglycosides (especially in Acinetobacter
spp and Klebsiella spp).
In last decade, highly resistant molecularly proved nosoco-
mial infections to broad spectrum antibiotics probably due to
production of betalactamases (for cephalosporins) or amino-
glycoside modifying enzymes (AME) have emerged in our area.
In this study Acinetobacter and Klebsiella resistance was due to
production of betalactamase and carbapenemase which could
highlight that Acinetobacter could be emerging as a multidrug
resistant organism (XDR-AB), conﬁrmed by the presence of the
metallo--lactamase (MBL) and OXA genes. K. pneumoniae (Kp)
producing carbapenemase (KPC) are associated with difﬁcult
to treat infections, and high mortality requiring combination
therapy with carbapenems to improve survival. Therefore, Kp
should not be overlooked as its resistance is emerging (25% of
isolates were KPC producing) and the Kp infections are advised
to be controlled with caution and using combination of a car-
bapenem, tigecycline, and colistin5 to lower mortality.
HAI, if not properly controlled, increase in mortality rates,
treatment costs, and reduces life span. Awareness of the resis-
tance mechanism could lead to adequate prescription and
ways to eliminate the resistance must be sought.
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